OGN

NYSE · Pharmaceuticals

Organon & Co

Mid-Cap Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$13.43

+0.01 (+0.07%)

As of Jun 21, 10:03 PM ET ·

Financial Highlights (FY 2026)

Revenue

6.26B

Net Income

188.18M

Gross Margin

53.3%

Profit Margin

3.0%

Rev Growth

+0.2%

D/E Ratio

11.49

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	53.3%	53.3%	28.3%	28.3%
Operating Margin	6.8%	6.2%	27.9%	29.6%
Profit Margin	3.0%	2.9%	28.0%	28.9%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	6.26B	6.24B	515.23M	479.67M
Gross Profit	3.33B	3.33B	145.97M	135.89M
Operating Income	427.86M	384.19M	143.74M	141.87M
Net Income	188.18M	168.97M	144.40M	138.60M
Gross Margin	53.3%	53.3%	28.3%	28.3%
Operating Margin	6.8%	6.2%	27.9%	29.6%
Profit Margin	3.0%	2.9%	28.0%	28.9%
Rev Growth	+0.2%	+0.2%	+11.5%	-9.2%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	1.62B	1.62B	937.97M	935.09M
Total Equity	141.13M	141.13M	1.31B	1.37B
D/E Ratio	11.49	11.49	0.71	0.68

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	584.68M	554.18M	186.20M	184.13M
Free Cash Flow	—	—	113.95M	97.08M